Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
W.A. Orenstein, P.M. Strebel, M. Papania, R.W. Sutter, W.J. Bellini, S.L. Cochi.
Measles eradication: is it in our future?.
Am J Public Health, 90 (2000), pp. 1521-1525
[2.]
P. Godoy, A. Domínguez, J. Alvarez, N. Camps, J.M. Jansa, S. Minguell.
Measles epidemiology in Catalonia (Spain): implications for a regional vaccination programme.
Int J Epidemiol, 28 (1999), pp. 558-562
[3.]
M. Meqdam, A. Mostratos.
Characterization of immune response.
to synthetic peptides derived from the hemagglutinin of measles virus. New Microbiol, 23 (2000), pp. 113-118
[4.]
P. Crovari, G. Gabutti, G. Giammanco, P. Dentico, A.R. Moiraghi, F. Ponzio.
Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
Vaccine, 18 (2000), pp. 2796-2803
[5.]
M. Paunio, K. Hedman, I. Davidkin, M. Valle, O.P. Heinonen, P. Leinikki.
Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age.
Epidemiol Infect, 124 (2000), pp. 263-271
[6.]
J. Klinge, S. Lugauer, K. Korn, U. Heininger, K. Stehr.
Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
Vaccine, 18 (2000), pp. 3134-3140
[7.]
M.A. Afzal, P.D. Minor, G.C. Schild.
Clinical safety issues of measles, mumps and rubella vaccines. Bull World Health.
Organ, 78 (2000), pp. 199-204
[8.]
J. Castell, E.F. Peiró, J.V. Rullán, A. Nieto-Sandoval.
Intervención en un brote de sarampión.
Enf Infec Microbiol Clin, 14 (1996), pp. 426-432
[9.]
A. Tischer, E. Gerike.
Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Vaccine, 18 (2000), pp. 1382-1392
Copyright © 2001. Asociación Española de Pediatría
